UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000007990
Receipt number R000009395
Scientific Title A phase II study of first line chemotherapy by eribulin mesilate for HER2 negative recurrent breast cancer
Date of disclosure of the study information 2012/05/19
Last modified on 2022/11/28 18:28:43

No. Disposal Last modified on Item of update
1 Insert 2012/05/19 15:39:34
2 Update 2012/05/19 15:47:11 Date of disclosure of the study information
3 Update 2012/05/19 16:14:14 Institutions
4 Update 2012/12/22 16:29:08 Email1
Institutions
5 Update 2012/12/22 16:34:49 Institutions
6 Update 2014/05/19 12:17:09 Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
7 Update 2014/05/19 12:19:44 Email
8 Update 2016/09/10 12:22:28 Name of primary person or sponsor
Organization
9 Update 2016/09/10 12:26:02 Institutions
10 Update 2016/11/26 15:25:38 Recruitment status
11 Update 2018/05/26 15:20:39 Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Publication of results
Results
12 Update 2022/11/28 18:13:52 Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
13 Update 2022/11/28 18:17:23 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code
Address
Address
TEL

Last name of contact person

Last name of contact person
Zip code
Address
Address
TEL
Email
Address1
Tel1
Email1
Organization
Organization
Address
Address
Tel
Email
14 Update 2022/11/28 18:28:43 Recruitment status
Date of IRB